BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• 

  Drug Development

  Pfizer Terminates Phase III Sickle Cell Study Due to Slow Patient Recruitment

  While Pfizer has ended one of its two Phase III studies for inclacumab in sickle cell disease, the company is still eyeing an approval for the antibody in the inherited blood disorder by 2026.

  March 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Psychosis: The Other Big Alzheimer’s Therapeutic Target

  While disease-modifying therapies largely steal the spotlight in Alzheimer’s drug development, several companies are working to solve this less-discussed but disruptive facet of the illness.

  March 27, 2024

   · 

  7 min read

   · 

  Sruthi S. Balakrishnan
• 

  Drug Development

  Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint

  Nanoscope Therapeutics nabbed a victory on the changed primary endpoint of its Phase IIb vision loss gene therapy trial Tuesday, teeing the biotech up to file for FDA approval of the candidate this year.

  March 27, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Drug Development

  Moderna Secures Up to $750M in Funding from Blackstone to Advance Flu Program

  Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.

  March 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Novocure Gets Phase III Win in Patients with Brain Metastases from Lung Cancer

  Novocure’s stock spiked more than 15% Wednesday morning after the company announced its Tumor Treating Fields therapy met the primary endpoint in a late-stage trial.

  March 27, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• 

  Avenzo Closes $150M Oversubscribed Series A-1 to Advance Cancer Therapies

  Avenzo Therapeutics on Tuesday said it will use the financing round to advance its next-generation oncology pipeline, including a potentially best-in-class CDK2 selective inhibitor.

  March 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Career Advice

  How to Set and Maintain Boundaries at Work

  To avoid overextending yourself and harming your work-life balance, how should you set and maintain boundaries at work?

  March 27, 2024

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Policy

  COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: GlobalData

  Data analytics firm GlobalData expects potential FDA approvals this year of Sanofi and Regeneron’s Dupixent and Verona’s ensifentrine to transform the treatment of chronic obstructive pulmonary disease.

  March 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  5 Top Companies Hiring in New Jersey

  Looking for a biopharma job in New Jersey? Check out the BioSpace list of five top companies hiring life sciences professionals like you.

  March 27, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Deals

  Opinion: AbbVie-Landos Deal Signals Continued Momentum for Next-Gen I&I Drugs

  Big Pharma’s appetite for safe and effective oral IBD drugs with novel mechanisms of action continues to grow, with my former company just the latest in a string of acquisitions in the space.

  March 27, 2024

   · 

  4 min read

   · 

  Josep Bassaganya-Riera